Table 4.
Top 11 related pathways in metascape for the ICH treatment of ZL capsule via ferroptosis.
| GO | Description | Count | % | Log10 (P) | Log10 (q) | Hits |
|---|---|---|---|---|---|---|
| hsa05200 | Pathways in cancer | 17 | 51.52 | −20.99 | −18.57 | CASP8, NQO1, EGFR, GSK3B, GSTP1, HMOX1, JUN, MYC, NFE2L2, MAPK1, PTEN, PTGS2, RB1, RELA, TGFB1, TGFB2, TP53 |
| hsa05161 | Hepatitis B | 10 | 30.3 | −14.91 | −12.85 | CASP8, JUN, MYC, MAPK1, RB1, RELA, TGFB1, TGFB2, TNF, TP53 |
| hsa05163 | Human cytomegalovirus infection | 10 | 30.3 | −13.47 | −11.63 | CASP8, EGFR, GSK3B, MYC, MAPK1, PTGS2, RB1, RELA, TNF, TP53 |
| hsa04657 | IL-17 signaling pathway | 8 | 24.24 | −13.07 | −11.44 | CASP8, GSK3B, JUN, MAPK1, PTGS2, RELA, TNF, TNFAIP3 |
| hsa05418 | Fluid shear stress and atherosclerosis | 8 | 24.24 | −11.69 | −10.39 | NQO1, GSTP1, HMOX1, JUN, NFE2L2, RELA, TNF, TP53 |
| hsa05208 | Chemical carcinogenesis - reactive oxygen species | 8 | 24.24 | −10.04 | −8.9 | NQO1, EGFR, HMOX1, JUN, NFE2L2, MAPK1, PTEN, RELA |
| hsa04216 | Ferroptosis | 5 | 15.15 | −9.08 | −7.99 | ALOX15, ACSL4, HMOX1, SLC3A2, TP53 |
| hsa01524 | Platinum drug resistance | 4 | 12.12 | −5.91 | −5.22 | CASP8, GSTP1, MAPK1, TP53 |
| hsa05012 | Parkinson disease | 5 | 15.15 | −5 | −4.39 | HSPA5, NFE2L2, SNCA, TP53, UCHL1 |
| hsa04217 | Necroptosis | 4 | 12.12 | −4.57 | −3.98 | ALOX15, CASP8, TNF, TNFAIP3 |
| hsa04370 | VEGF signaling pathway | 3 | 9.09 | −4.43 | −3.86 | HSPB1, MAPK1, PTGS2 |